IL6 and chronic obstructive pulmonary disease: Our immunofluorescence results also demonstrated that IL-6 levels in the COPD were significantly higher than those in the normal group, and that the reduction in its levels also had a dose-dependent relationship for the HPMHD treatment, further confirming the relationship between IL-6 and COPD disease targets and fully elucidating the target of HPMHD for reversing mouse model of COPD.